Please login to the form below

Not currently logged in
Email:
Password:

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

Joined by John Womelsdorf who is appointed VP business development

Jan De Vries, AIMM TherapeuticsAIMM Therapeutics has appointed former VP and head of the Novartis Research Institutes for Biomedical Research Jan de Vries (pictured) as its new CEO.

He is joined at the Amsterdam-based biotech company by John Womelsdorf, who becomes the antibody specialist's VP of business development.

Their appointments signal AIMM's intention to build on its antibody programmes, which already include collaborations with large pharma companies in infectious diseases, and expand its partnership efforts into both cancer and autoimmune conditions.

Tom Schwarz, AIMM's chair, said: “Jan de Vries has deep experience in drug discovery and early development and was involved in developing many successful, currently marketed drugs. We are pleased to have attracted him to lead AIMM Therapeutics, as the company transitions to become one of the major players in the next-generation antibody space.”

During his time at Novartis, de Vries led the discovery and early development of several drugs including Elidel (pimecrolimus) for eczema, Ilaris (canakunimab) for cryopyrin-associated periodic syndromes, Gilenya (fingolimod) for multiple sclerosis and secukinumab for several inflammatory conditions. 

Prior to joining Novartis, de Vries worked at the DNAX Research Institute for Molecular Biological Research following a spell as co-director of the Schering–Plough Institute for Immunological Research in Lyon, France.

He entered the pharma industry having spent several years in academic positions at the Netherlands Cancer Institute in Amsterdam, where he was Head of the Immunology Department.

Meanwhile, Womelsdorf has more than 16 years' experience in senior business development roles at several companies, including Optimer Pharmaceuticals, Cyclacel Pharmaceuticals, J&J, Roche, and Baxter International.

12th November 2012

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics